Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state

Anesthesiology

Volumn 118, Issue 1, 2013, Pages 160-172

  Suter, Marc R ^a   Kirschmann, Guylène ^a   Laedermann, Cedric J ^b   Abriel, Hugues ^c   Decosterd, Isabelle ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b University Hospital Center   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; MEXILETINE; R 8404; RUFINAMIDE; SODIUM CHANNEL NAV1.7; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; IN VITRO STUDY; MALE; MECHANICAL STIMULATION; MOUSE; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; SPINAL GANGLION;

AMITRIPTYLINE; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; HYPERALGESIA; MICE; MICE, INBRED C57BL; NEURALGIA; PHYSICAL STIMULATION; TRIAZOLES; VOLTAGE-GATED SODIUM CHANNELS;

EID: 84871612770     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318278cade     Document Type: Article

References (79)

1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D: Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10:287-333
2. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG: Sodium channels in normal and pathological pain. Annu Rev Neurosci 2010; 33:325-47
3. Berta T, Poirot O, Pertin M, Ji RR, Kellenberger S, Decosterd I: Transcriptional and functional profles of voltage-gated Na(+) channels in injured and non-injured DRG neurons in the SNI model of neuropathic pain. Mol Cell Neurosci 2008; 37:196-208 (Pubitemid 351173844)
4. Suter MR, Siegenthaler A, Decosterd I, Ji RR: Perioperative nerve blockade: Clues from the bench. Anesthesiol Res Pract 2011; 2011:124898
5. Devor M: Responses of nerves to injury in relation to neu-ropathic pain, Textbook of Pain, 5th edition. Edited by Mc Mahon SB, Koltzenburg M. Elsevier, 2006, pp 905-28
6. Catterall WA, Goldin AL, Waxman SG: International Union of Pharmacology XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 2005; 57:397-409 (Pubitemid 43036431)
7. Besson M, Piguet V, Dayer P, Desmeules J: New approaches to the pharmacotherapy of neuropathic pain. Expert Rev Clin Pharmacol 2008; 1: 683-93
8. Freynhagen R, Bennett MI: Diagnosis and management of neuropathic pain. BMJ 2009; 339:b3002
9. Saarto T, Wiffen PJ: Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; Oct 17;(4):CD005454
10. Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT: Sodium channel blockade may contribute to the analgesic effcacy of antidepressants. J Pain 2007; 8:315-24 (Pubitemid 46551873)
11. Challapalli V, Tremont-Lukats IW, Mc Nicol ED, Lau J, Carr DB: Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2005; Oct 19;(4):CD003345
12. Carroll IR, Kaplan KM, Mackey SC: Mexiletine therapy for chronic pain: Survival analysis identifes factors predicting clinical success. J Pain Symptom Manage 2008; 35:321-6
13. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S: Rufnamide for generalized seizures associ-ated with Lennox-Gastaut syndrome. Neurology 2008; 70: 1950-8
14. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, Mc Hale DP, Wood JN, Gribble FM, Woods CG: An SCN9A channelo-pathy causes congenital inability to experience pain. Nature 2006; 444:894-8 (Pubitemid 46024997)
15. Lampert A, O'Reilly AO, Reeh P, Leffer A: Sodium channelo-pathies and pain. Pfugers Arch 2010; 460:249-63
16. Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, Choi JS, Estacion M, Lauria G, Vanhoutte EK, Gerrits MM, Dib-Hajj S, Drenth JP, Waxman SG, Merkies IS: Gain of function Naν1.7 mutations in idiopathic small fber neuropathy. Ann Neurol 2012; 71:26-39
17. Dabby R, Sadeh M, Gilad R, Lampl Y, Cohen S, Inbar S, Leshinsky-Silver E: Chronic non-paroxysmal neuropathic pain \- Novel phenotype of mutation in the sodium channel SCN9A gene. J Neurol Sci 2011; 301:90-2
18. Black JA, Dib-Hajj S, Mc Nabola K, Jeste S, Rizzo MA, Kocsis JD, Waxman SG: Spinal sensory neurons express multiple sodium channel alpha-subunit m RNAs. Brain Res Mol Brain Res 1996; 43:117-31 (Pubitemid 27042398)
19. Sangameswaran L, Fish LM, Koch BD, Rabert DK, Delgado SG, Ilnicka M, Jakeman LB, Novakovic S, Wong K, Sze P, Tzoumaka E, Stewart GR, Herman RC, Chan H, Eglen RM, Hunter JC: A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root gan-glia. J Biol Chem 1997; 272:14805-9 (Pubitemid 27251749)
20. Toledo-Aral JJ, Moss BL, He ZJ, Koszowski AG, Whisenand T, Levinson SR, Wolf JJ, Silos-Santiago I, Halegoua S, Mandel G: Identifcation of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci USA 1997; 94:1527-32 (Pubitemid 27087885)
21. Herzog RI, Cummins TR, Ghassemi F, Dib-Hajj SD, Waxman SG: Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sen-sory neurons. J Physiol (Lond) 2003; 551(Pt 3):741-50 (Pubitemid 37221069)
22. Cummins TR, Sheets PL, Waxman SG: The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain 2007; 131:243-57 (Pubitemid 47374344)
23. Cummins TR, Howe JR, Waxman SG: Slow closed-state inacti-vation: A novel mechanism underlying ramp currents in cells expressing the h NE/PN1 sodium channel. J Neurosci 1998; 18:9607-19 (Pubitemid 28543742)
24. White HS, Franklin MR, Kupferberg HJ, Schmutz M, Stables JP, Wolf HH: The anticonvulsant profle of rufnamide (CGP 33101) in rodent seizure models. Epilepsia 2008; 49: 1213-20 (Pubitemid 351991388)
25. Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16:109-10 (Pubitemid 13058546)
26. Decosterd I, Woolf CJ: Spared nerve injury: An animal model of persistent peripheral neuropathic pain. Pain 2000; 87:149-58 (Pubitemid 30621447)
27. Suter MR, Papaloïzos M, Berde CB, Woolf CJ, Gilliard N, Spahn DR, Decosterd I: Development of neuropathic pain in the rat spared nerve injury model is not prevented by a peripheral nerve block. ANESTHESIOLOGY 2003; 99:1402-8 (Pubitemid 37475188)
28. Bourquin AF, Süveges M, Pertin M, Gilliard N, Sardy S, Davison AC, Spahn DR, Decosterd I: Assessment and analy-sis of mechanical allodynia-like behavior induced by spared nerve injury (SNI) in the mouse. Pain 2006; 122:14.e1-14
29. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55-63 (Pubitemid 24238751)
30. Boast CA, Pastor G, Gerhardt SC, Hall NR, Liebman JM: Behavioral tolerance and sensitization to CGS 19755, a competitive N-methyl-D-aspartate receptor antagonist. J Pharmacol Exp Ther 1988; 247:556-61
31. Ardid D, Guilbaud G: Antinociceptive effects of acute and 'chronic' injections of tricyclic antidepressant drugs in a new model of mononeuropathy in rats. Pain 1992; 49:279-87
32. Yasuda T, Iwamoto T, Ohara M, Sato S, Kohri H, Noguchi K, Senba E: The novel analgesic compound OT-7100 (5-n-butyl-7-(3,4,5-trimethoxybenzoylamino) pyrazolo[1,5-a]pyrimid ine) attenuates mechanical nociceptive responses in animal models of acute and peripheral neuropathic hyperalgesia. Jpn J Pharmacol 1999; 79:65-73 (Pubitemid 29060549)
33. Abdi S, Lee DH, Chung JM: The anti-allodynic effects of ami-triptyline, gabapentin, and lidocaine in a rat model of neuro-pathic pain. Anesth Analg 1998; 87:1360-6 (Pubitemid 28549506)
34. Esser MJ, Chase T, Allen GV, Sawynok J: Chronic adminis-tration of amitriptyline and caffeine in a rat model of neu-ropathic pain: Multiple interactions. Eur J Pharmacol 2001; 430:211-8 (Pubitemid 33050040)
35. Pradhan AA, Yu XH, Laird JM: Modality of hyperalgesia tested, not type of nerve damage, predicts pharmacological sensitivity in rat models of neuropathic pain. Eur J Pain 2010; 14:503-9
36. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A: Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 1994; 57:153-60 (Pubitemid 24168732)
37. Mao QX, Yang TD: Amitriptyline upregulates EAAT1 and EAAT2 in neuropathic pain rats. Brain Res Bull 2010; 81:424-7
38. Decosterd I, Allchorne A, Woolf CJ: Differential analgesic sensitivity of two distinct neuropathic pain models. Anesth Analg 2004; 99:457-63 (Pubitemid 38970420)
39. Arsenault A, Sawynok J: Perisurgical amitriptyline produces a preventive effect on afferent hypersensitivity following spared nerve injury. Pain 2009; 146:308-14
40. Rode F, Thomsen M, Broløs T, Jensen DG, Blackburn-Munro G, Bjerrum OJ: The importance of genetic background on pain behaviours and pharmacological sensitivity in the rat spared serve injury model of peripheral neuropathic pain. Eur J Pharmacol 2007; 564:103-11 (Pubitemid 46946854)
41. Hama AT, Borsook D: The effect of antinociceptive drugs tested at different times after nerve injury in rats. Anesth Analg 2005; 101:175-9 (Pubitemid 40853372)
42. Erichsen HK, Hao JX, Xu XJ, Blackburn-Munro G: A compari-son of the antinociceptive effects of voltage-activated Na+ channel blockers in two rat models of neuropathic pain. Eur J Pharmacol 2003; 458:275-82 (Pubitemid 36009466)
43. Broom DC, Samad TA, Kohno T, Tegeder I, Geisslinger G, Woolf CJ: Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. Neuroscience 2004; 124:891-900 (Pubitemid 38328778)
44. Erichsen HK, Blackburn-Munro G: Pharmacological charac-terisation of the spared nerve injury model of neuropathic pain. Pain 2002; 98:151-61 (Pubitemid 34722477)
45. Rojas-Corrales MO, Casas J, Moreno-Brea MR, Gibert-Rahola J, Micó JA: Antinociceptive effects of tricyclic anti-depressants and their noradrenergic metabolites. Eur Neuropsychopharmacol 2003; 13:355-63 (Pubitemid 37040918)
46. Matson DJ, Broom DC, Carson SR, Baldassari J, Kehne J, Cortright DN: Infammation-induced reduction of spontaneous activity by adjuvant: A novel model to study the effect of analgesics in rats. J Pharmacol Exp Ther 2007; 320:194-201 (Pubitemid 46025734)
47. Enginar N, Hatipolu I, Firtina M: Evaluation of the acute effects of amitriptyline and fuoxetine on anxiety using grooming analysis algorithm in rats. Pharmacol Biochem Behav 2008; 89:450-5
48. Ogren SO, Cott JM, Hall H: Sedative/anxiolytic effects of antidepressants in animals. Acta Psychiatr Scand Suppl 1981; 290:277-88 (Pubitemid 11156120)
49. Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ: Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharma-cological characterization of diverse classes of antidepres-sant agents. Pharmacol Biochem Behav 2002; 71:667-80 (Pubitemid 34219217)
50. Paudel KR, Das BP, Rauniar GP, Sangraula H, Deo S, Bhattacharya SK: Antinociceptive effect of amitriptyline in mice of acute pain models. Indian J Exp Biol 2007; 45:529-31
51. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS: Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007; 132:237-51 (Pubitemid 350051570)
52. Sudoh Y, Cahoon EE, Gerner P, Wang GK: Tricyclic antidepres-sants as long-acting local anesthetics. Pain 2003; 103:49-55 (Pubitemid 36579084)
53. Wang SY, Calderon J, Kuo Wang G: Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. ANESTHESIOLOGY 2010; 113:655-65
54. Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P; EFNS Task Force: EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13:1153-69 (Pubitemid 44581463)
55. Robinson LR, Czerniecki JM, Ehde DM, Edwards WT, Judish DA, Goldberg ML, Campbell KM, Smith DG, Jensen MP: Trial of amitriptyline for relief of pain in amputees: Results of a ran-domized controlled study. Arch Phys Med Rehabil 2004; 85:1-6 (Pubitemid 38049583)
56. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fuoxetine on pain in diabetic neuropathy N Engl J Med 1992; 326:1250-6
57. Baldessarini RJ: Drug therapy of depression and anxiety disorders, Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th edition. Edited by Shanahan F, Foltin J, Edmonson K, Brown RY. New York, The Mc Graw-Hill Companies, 2006, pp 429-60
58. Holmberg G: Sedative effects of maprotiline and amitripty-line. Acta Psychiatr Scand 1988; 77:584-6
59. Swift CG, Haythorne JM, Clarke P, Stevenson IH: Cardiovascular, sedative and anticholinergic effects of ami-triptyline and zimelidine in young and elderly volunteers. Acta Psychiatr Scand Suppl 1981; 290:425-32 (Pubitemid 11156135)
60. Perucca E, Cloyd J, Critchley D, Fuseau E: Rufnamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy Epilepsia 2008; 49:1123-41 (Pubitemid 351991401)
61. Fava M: The possible antianxiety and mood-stabilizing effects of rufnamide. Psychother Psychosom 2010; 79:194-5
62. Mc Williams LA, Goodwin RD, Cox BJ: Depression and anx-iety associated with three pain conditions: Results from a nationally representative sample. Pain 2004; 111:77-83 (Pubitemid 39141009)
63. Bhattacharya A, Wickenden AD, Chaplan SR: Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeutics 2009; 6:663-78
64. Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak A, Darling M, Gore A, Jang GR, Kesslak JP, Ni L, Norman MH, Palluconi G, Rose MJ, Salf M, Tan E, Romanovsky AA, Banfeld C, Davar G: Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008; 136:202-10
65. Wallace MS, Rowbotham M, Bennett GJ, Jensen TS, Pladna R, Quessy S: A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain. J Pain 2002; 3:227-33 (Pubitemid 34663612)
66. Nau C, Seaver M, Wang SY, Wang GK: Block of human heart h H1 sodium channels by amitriptyline. J Pharmacol Exp Ther 2000; 292:1015-23 (Pubitemid 30136596)
67. Weiser T, Qu Y, Catterall WA, Scheuer T: Differential interac-tion of R-mexiletine with the local anesthetic receptor site on brain and heart sodium channel alpha-subunits. Mol Pharmacol 1999; 56:1238-44
68. Wang GK, Russell C, Wang SY: State-dependent block of volt-age-gated Na+ channels by amitriptyline via the local anes-thetic receptor and its implication for neuropathic pain. Pain 2004; 110:166-74 (Pubitemid 38953280)
69. Payandeh J, Scheuer T, Zheng N, Catterall WA: The crystal structure of a voltage-gated sodium channel. Nature 2011; 475:353-8
70. Hudson LJ, Bevan S, Mc Nair K, Gentry C, Fox A, Kuhn R, Winter J: Metabotropic glutamate receptor 5 upregulation in A-fbers after spinal nerve injury: 2-methyl-6-(phenylethynyl)-pyridine (MPEP) reverses the induced thermal hyperalgesia. J Neurosci 2002; 22:2660-8 (Pubitemid 37465815)
71. Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Veliçelebi G, Kuhn R: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active m Glu5 receptor antagonist. Neuropharmacology 1999; 38:1493-503 (Pubitemid 29457731)
72. Walker K, Bowes M, Panesar M, Davis A, Gentry C, Kesingland A, Gasparini F, Spooren W, Stoehr N, Pagano A, Flor PJ, Vranesic I, Lingenhoehl K, Johnson EC, Varney M, Urban L, Kuhn R: Metabotropic glutamate receptor subtype 5 (m Glu5) and nociceptive function. I. Selective blockade of m Glu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology 2001; 40:1-9 (Pubitemid 33779794)
73. Zhu CZ, Wilson SG, Mikusa JP, Wismer CT, Gauvin DM, Lynch JJ III, Wade CL, Decker MW, Honore P: Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 2004; 506:107-18 (Pubitemid 39592907)
74. Dogrul A, Ossipov MH, Lai J, Malan TP Jr, Porreca F: Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (m GLUR(5)) antagonist, in experimental neuropathic pain in rats. Neurosci Lett 2000; 292:115-8
75. Fisher K, Fundytus ME, Cahill CM, Coderre TJ: Intrathecal administration of the m Glu R compound, (S)-4CPG, attenuates hyperalgesia and allodynia associated with sciatic nerve constriction injury in rats. Pain 1998; 77:59-66 (Pubitemid 28398834)
76. Fisher K, Lefebvre C, Coderre TJ: Antinociceptive effects fol-lowing intrathecal pretreatment with selective metabotropic glutamate receptor compounds in a rat model of neuropathic pain. Pharmacol Biochem Behav 2002; 73:411-8 (Pubitemid 34765578)
77. Coppen A, Ghose K, Montgomery S, Rama Rao VA, Bailey J, Christiansen J, Mikkleson PL, van Praag HM, van de Poel F, Minsker EJ, Kozulja VG, Matussek N, Kungkunz G, Jłrgensen A: Amitriptyline plasma-concentration and clinical effect. A World Health Organisation Collaborative Study. Lancet 1978; 1:63-6
78. Cavaletti G, Oggioni N, Sala F, Pezzoni G, Cavalletti E, Marmiroli P, Petruccioli MG, Frattola L, Tredici G: Effect on the peripheral nervous system of systemically administered dimethylsulfoxide in the rat: A neurophysiological and path-ological study. Toxicol Lett 2000; 118:103-7 (Pubitemid 32008400)
79. Brien S, Prescott P, Bashir N, Lewith H, Lewith G: Systematic review of the nutritional supplements dimethyl sulfox-ide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthr Cartil 2008; 16: 1277-88